Merck & Co., Inc.
HealthcareNYSE:MRK · New York Stock Exchange
-$0.74 today
Vol 4.66M · Avg 9.70M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
34.7%
avg 23.1%
ROIC
18.3%
avg 10.2%
ROA
13.3%
avg 8.4%
Analysis
ROE is currently the strongest return metric at 34.7% versus its period average of 23.1%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Davis | Chairman, President & Chief Executive Officer | $4.63M | — | 59 | $139,697.00 | <0.01% |
Dean Y. Li | Executive Vice President & President of Merck Research Laboratories | $3.00M | — | 63 | $58,207.00 | <0.01% |
Caroline Litchfield | Executive Vice President & Chief Financial Officer | $2.40M | — | 57 | $46,566.00 | <0.01% |
Betty D. Larson | Executive Vice President & Chief Human Resources Officer | $2.29M | — | 50 | $23,283.00 | <0.01% |
Jennifer L. Zachary | Executive Vice President & General Counsel | $2.17M | — | 48 | $35,312.00 | <0.01% |
Richard R. DeLuca Jr. | Executive Vice President & President of Merck Animal Health | $2.17M | — | 63 | $11,931.00 | <0.01% |
Sanat Chattopadhyay | Executive Vice President & President of Merck Manufacturing Division | $2.09M | — | 66 | $16,477.00 | <0.01% |
Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications | $1.54M | — | 60 | $19,402.00 | <0.01% |
Eliav Barr | Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories | — | — | 61 | — | — |
Eric H. Rubin | Senior Vice President of Global Clinical Oncology & Early-stage Oncology | — | — | 66 | — | — |
David Michael Williams | Executive Vice President and Chief Information & Digital Officer | — | — | 57 | $21,731.00 | <0.01% |
Joerg Koglin | Senior VP & Head of General Medicine - Global Clinical Development | — | — | — | — | — |
Dalton E. Smart | Senior Vice President of Finance, Principal Accounting Officer & Global Controller | — | — | 59 | $5,045.00 | <0.01% |
Johannes J. Oosthuizen | Executive VP and President of Oncology & MSD International | — | — | 58 | $34,944.93 | <0.01% |
Peter Dannenbaum | Vice President of Investor Relations | — | — | — | $124,752.62 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$32.18M
Net Sentiment
$32.18M
Net selling
Most Active
Guindo Chirfi
3 transactions
1–10 of 16
Analysis
Insiders reported 0 buys worth $0.00 and 16 sells worth $32.18M over the last 12 months. That adds up to net selling of $32.18M. Guindo Chirfi was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -10.3% | +13.2% (15yr)1 analysts |
| Revenue | N/A | N/A | -5.8% | +4.3% (15yr)2 analysts |
| Net Income | N/A | N/A | -10.4% | +12.2% (15yr)2 analysts |
| EBIT | N/A | N/A | -8.6% | +10.1% (15yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at -5.8% over three years. Forward estimates point to EPS at +13.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Novartis AG
NYSE:NVS
$292.83B
AstraZeneca PLC
NYSE:AZN
$278.74B
Novo Nordisk A/S
NYSE:NVO
$196.44B
Amgen Inc.
NASDAQ:AMGN
$191.12B
Thermo Fisher Scientific Inc.
NYSE:TMO
$174.59B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.61B
Abbott Laboratories
NYSE:ABT
$153.01B
Pfizer Inc.
NYSE:PFE
$149.30B
GSK plc
NYSE:GSK
$106.61B
Sanofi
NASDAQ:SNY
$106.50B
Who manages MRK?
Merck & Co., Inc. (MRK) lists 15 active executives. The top listed executive is Dean Y. Li, Executive Vice President & President of Merck Research Laboratories.
Are MRK insiders buying or selling?
Recent insider activity shows net buying of $86.49M.
Explore More
Continue the stock analysis
Jump to another research area for this company.